NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/07/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization271.27 mln
Float27.47 mln
Earnings Date08/13/2026
Beneish M-Score
-3.24
Reliable
Relative Strength
96
/ 100
Top performer
Debt / Equity
0.07
Debt-free
ROE
-189
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Camp4 Therapeutics is a clinical-stage company focused on developing RNA-based treatments for inherited genetic diseases. Its lead drug, CMP-001, is currently being tested in an early-stage clinical trial for urea cycle disorders, while a second treatment, CMP-002, targets SYNGAP1-related conditions. Founded in 2015 and based in Cambridge, Massachusetts, the company was previously called Marauder Therapeutics before rebranding in 2018.
